Your browser doesn't support javascript.
loading
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons.
Convertino, Irma; Lucenteforte, Ersilia; Gini, Rosa; Lorenzoni, Valentina; Cazzato, Massimiliano; Turchetti, Giuseppe; Trieste, Leopoldo; Ferraro, Sara; Leonardi, Luca; Roberto, Giuseppe; Luciano, Nicoletta; Blandizzi, Corrado; Mosca, Marta; Tuccori, Marco.
Afiliação
  • Convertino I; Pharmacology and Pharmacovigilance Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  • Lucenteforte E; Medical Statistics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  • Gini R; Tuscan Regional Healthcare Agency, Florence, Italy.
  • Lorenzoni V; Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy.
  • Cazzato M; Rheumatology Unit, University Hospital of Pisa, Italy.
  • Turchetti G; Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy.
  • Trieste L; Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy.
  • Ferraro S; Pharmacology and Pharmacovigilance Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  • Leonardi L; Pharmacology and Pharmacovigilance Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  • Roberto G; Tuscan Regional Healthcare Agency, Florence, Italy.
  • Luciano N; Rheumatology Unit, University Hospital of Pisa, Italy.
  • Blandizzi C; Pharmacology and Pharmacovigilance Unit, Department of Clinical and Experimental Medicine, and Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, Italy.
  • Mosca M; Rheumatology Unit, University Hospital of Pisa, Italy.
  • Tuccori M; Pharmacology and Pharmacovigilance Unit, Department of Clinical and Experimental Medicine, and Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, Italy. m.tuccori@ao-pisa.toscana.it.
Clin Exp Rheumatol ; 39(4): 753-762, 2021.
Article em En | MEDLINE | ID: mdl-32828145
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicamentos Biossimilares Tipo de estudo: Guideline Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicamentos Biossimilares Tipo de estudo: Guideline Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article